Abstract PD18-11: Dose-Expansion Study of Trastuzumab Deruxtecan as Monotherapy or Combined With Pertuzumab in Patients With Metastatic Human Epidermal Growth Factor Receptor 2-Positive (HER2+) Breast Cancer in DESTINY-Breast07 (DB-07)
Erika Hamilton(Sarah Cannon), Fabrice André(Inserm), Carey K. Anders(Duke University), Konstantin Penkov, Shoubhik Mondal, Е. В. Артамонова, Flavia Michelini(Memorial Sloan Kettering Cancer Center), Sarice R Boston(University of Maryland, Baltimore), Sarat Chandarlapaty(Memorial Sloan Kettering Cancer Center), Komal Jhaveri(Memorial Sloan Kettering Cancer Center), Peter Schmid(London Cancer), Adam Konpa(AstraZeneca (Poland)), Lyudmila Zhukova(Moscow Clinical Scientific Center), Dinesh Chandra Doval(Rajiv Gandhi Cancer Institute and Research Centre), Matt Wilson(AstraZeneca (United Kingdom)), Daniil Stroyakovsky(Moscow City Oncology Hospital №62), Sherene Loi(The University of Melbourne)
Cited by 5
Related Papers
OncoKB: A Precision Oncology Knowledge Base
|JCO Precision Oncology|2017|2.7k
3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)
|Annals of Oncology|2016|2.1k
AACR Project GENIE: Powering Precision Medicine through an International Consortium
|Cancer Discovery|2017|2k